{"entity":{"id":"nct06176261","kind":"trial","name":"DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs","aka":[],"tldr":"A phase 2 trial of datopotamab deruxtecan in triple-negative breast cancer, run by Nancy Lin, MD, now recruiting.","summary":"DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs is a phase 2, interventional study registered as NCT06176261 by Nancy Lin, MD, with a registry enrolment figure of 58 participants, started 2024-01-08 and due to reach its primary completion in 2028-01-01. Interventions recorded: Datopotamab Deruxtecan. Conditions listed: Breast Cancer; Breast Cancer Female; Metastatic Triple-Negative Breast Carcinoma; ER Positive Breast Cancer; HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma; ER-negative Breast Cancer. Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06176261","url":"https://clinicaltrials.gov/study/NCT06176261"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic","brain-metastases"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["datopotamab-deruxtecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06176261","phase":"2","setting":"DATO-BASE: A Phase 2 Trial of DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs","sponsor":"Nancy Lin, MD","enrolled":58,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06176261/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"term":[{"id":"brain-metastases","kind":"term","name":"Brain metastases (intracranial disease)","route":"/terms/brain-metastases/"},{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"}]}}